# Methadone for 'Adenocarcinopathic' Pain Treatment

> **NCT05325164** · PHASE3 · WITHDRAWN · sponsor: **Ottawa Hospital Research Institute**

## Conditions studied

- Cancer Pain
- Adenocarcinoma

## Interventions

- **DRUG:** Methadone
- **DRUG:** Morphine

## Key facts

- **NCT ID:** NCT05325164
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09
- **Primary completion:** 2023-08
- **Final completion:** 2023-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by new Sponsor/Investigator if it is started.
- **Last updated:** 2022-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05325164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05325164, "Methadone for 'Adenocarcinopathic' Pain Treatment". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05325164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*